Guillain–Barré syndrome after myocardial infarction

2003 ◽  
Vol 90 (1) ◽  
pp. 129-130 ◽  
Author(s):  
E. Ng ◽  
P.J. Stafford
Keyword(s):  
Myocardial Infarction ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barre syndrome after myocardial infarction.

BMJ ◽  
1987 ◽  
Vol 294 (6572) ◽  
pp. 613-614 ◽  
Author(s):  
A J McDonagh ◽  
J Dawson
Keyword(s):  
Myocardial Infarction ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain Barré Syndrome after Thrombolysis With Streptokinase for Acute Myocardial Infarction: A Case Report

2017 ◽  
Vol 33 (2) ◽  
pp. 103-104
Author(s):  
Mohammad Kafil Uddin ◽  
- Md Shahidullah ◽  
Subash Kanti Dey ◽  
Rezaul Karim Khan ◽  
Md Rafiqul Islam ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Case Report ◽  
Thrombolytic Therapy ◽  
Intravenous Immunoglobulin ◽  
Guillain Barre Syndrome ◽  
Neurologic Disorder ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

We would like to report on a patient, a 52-year-old man with acute neurologic disorder, Guillain Barré Syndrome. He was successfully treated by intravenous immunoglobulin. The patient suffered from acute extensive anterior MI. 2 weeks after thrombolytic therapy with streptokinase, he developed GBS. Bangladesh Journal of Neuroscience 2017; Vol. 33 (2): 103-104

scholarly journals Guillain-Barré syndrome following heart transplantation complicated by myocardial infarction following treatment with IVIg

2017 ◽  
Vol 4 (3) ◽  
pp. 39
Author(s):  
Joshua Newman ◽  
Andrew Chen ◽  
Saud Rana ◽  
Max Liebo
Keyword(s):  
Myocardial Infarction ◽  
Heart Transplantation ◽  
Systolic Dysfunction ◽  
Significant Coronary Artery Disease ◽  
Guillain Barre Syndrome ◽  
Treatment Modalities ◽  
Ivig Infusion ◽  
Transplant Patients ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Guillain-Barré syndrome (GBS) is rare autoimmune polyneuropathy that is infrequently seen in the post-transplant population, presumably due to the presence of immunosuppression. When it does occur in this setting, Cytomegalovirus (CMV) infection is a common inciting factor. Treatment modalities for GBS include intravenous immunoglobulin (IVIg) or plasmapheresis. Rarely, IVIg infusion has been associated with myocardial infarction. We describe a case of a patient status post heart transplantation who presented with GBS shortly after developing CMV viremia. When treatment with IVIg was initiated, our patient developed myocardial infarction with acute cardiac biomarker elevation, acute systolic dysfunction, and cardiogenic shock requiring inotropic and vasopressor support. Coronary angiography demonstrated no significant coronary artery disease. The patient’s cardiac function recovered, as did the GBS following initiation of plasmapheresis. We review prior cases of GBS in transplant patients as well as IVIg associated myocardial infarction.

Guillain–Barré syndrome after acute myocardial infarction: A rare presentation

2014 ◽  
Vol 11 (2) ◽  
pp. 110-114
Author(s):  
Pankaj Jariwala ◽  
Harikishan Boorugu ◽  
Gopal Chevuru ◽  
Arshad Punjani ◽  
Shaeq Mirza ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Guillain Barre Syndrome ◽  
Rare Presentation ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barre Syndrome and Myocardial Infarction

1990 ◽  
Vol 10 (2) ◽  
pp. 220-221
Author(s):  
K. Ashouri ◽  
A. K. Foli ◽  
A. Singhal
Keyword(s):  
Myocardial Infarction ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study

2021 ◽  
Author(s):  
Xintong Li ◽  
Anna Ostropolets ◽  
Rupa Makadia ◽  
Azza Shoaibi ◽  
Gowtham Rao ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cohort Study ◽  
Adverse Events ◽  
Special Interest ◽  
Incidence Rates ◽  
Guillain Barre Syndrome ◽  
Administrative Claims ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Age And Sex

As large-scale immunization programs against COVID-19 proceed around the world, safety signals will emerge that need rapid evaluation.1,2 We report population-based, age- and sex-specific background incidence rates of potential adverse events of special interest (AESI) in eight countries using thirteen databases. This multi-national network cohort study included eight electronic medical record and five administrative claims databases from Australia, France, Germany, Japan, Netherlands, Spain, the United Kingdom and the United States, mapped to a common data model. People observed for at least 365 days before 1 January 2017, 2018, or 2019 were included. We based study outcomes on lists published by regulators: acute myocardial infarction, anaphylaxis, appendicitis, Bell s palsy, deep vein thrombosis, disseminated intravascular coagulation, encephalomyelitis, Guillain-Barre syndrome, hemorrhagic and non-hemorrhagic stroke, immune thrombocytopenia, myocarditis/pericarditis, narcolepsy, pulmonary embolism, and transverse myelitis.3 We calculated incidence rates stratified by age, sex, and database. We pooled rates across databases using random effects meta-analyses. We classified meta-analytic estimates into Council of International Organizations of Medical Sciences categories: very common, common, uncommon, rare, or very rare.4 We analyzed 126,661,070 people. Rates varied greatly between databases and by age and sex. Some AESI (e.g., myocardial infarction, Guillain-Barre syndrome) increased with age, while others (e.g., anaphylaxis, appendicitis) were more common in young people. As a result, AESI were classified differently according to age. For example, myocardial infarction was very rare in children, rare in women aged 35-54 years, uncommon in men and women aged 55-84 years, and common in those aged ≥85 years. We report robust baseline rates of prioritized AESI across 13 databases. Age, sex, and variation between databases should be considered if background AESI rates are compared to event rates observed with COVID-19 vaccines.

Sign in / Sign up

Export Citation Format

Share Document